MedCAC Review Of ESAs In Renal Disease To Help Determine Need For NCD

The Medicare Evidence Development and Coverage Advisory Committee's review of the use of erythropoiesis-stimulating agents in chronic kidney disease is a first step toward determining whether the Centers for Medicare and Medicaid Services should open a national coverage determination process on Medicare payments for such treatment, according to CMS Chief Medical Officer Barry Straube